Innovation in midlife health and beyond.

@article{Seungdamrong2013InnovationIM,
  title={Innovation in midlife health and beyond.},
  author={Aimee Seungdamrong and Lubna Pal and Margaret N. Rees},
  journal={Maturitas},
  year={2013},
  volume={76 3},
  pages={205-7}
}
This special issue on innovation in midlife health and beyond akes a holistic approach to both reproductive and non reproductive ealth and development of new therapeutic approaches. Starting ith the controversies on hormone therapy with the first publicaions of the Women’s Health Initiative (WHI) results a decade ago, reas covered are gynecology and menopause, conditions affecting idlife health, drug development and novel research strategies to aintain reproductive function. Sanaz Shazal and… CONTINUE READING

Connections & Topics

Mentioned Connections BETA
Thus the ho are healthy and chronologically young perimenopausal and arly menopausal women , the when is within 10 years of onset of enopause and the what are lower dose regimens preferentially tilizing a transdermal approach for estrogen delivery and cyclic rogestin exposure , preferentially using natural progesterone for ndometrial protection .
Thus the ho are healthy and chronologically young perimenopausal and arly menopausal women , the when is within 10 years of onset of enopause and the what are lower dose regimens preferentially tilizing a transdermal approach for estrogen delivery and cyclic rogestin exposure , preferentially using natural progesterone for ndometrial protection .
A new alternative to menopausal hormone therapy is the tisue selective estrogen complex ( TSEC ) , which partners a selective strogen receptor modulator ( SERM ) with an estrogen [ 2 ] .
The first SEC to reach advanced clinical development is a combination of he SERM bazedoxifene ( BZA ) with conjugated estrogens ( CE ) .
A new alternative to menopausal hormone therapy is the tisue selective estrogen complex ( TSEC ) , which partners a selective strogen receptor modulator ( SERM ) with an estrogen [ 2 ] .
A new alternative to menopausal hormone therapy is the tisue selective estrogen complex ( TSEC ) , which partners a selective strogen receptor modulator ( SERM ) with an estrogen [ 2 ] .
A new alternative to menopausal hormone therapy is the tisue selective estrogen complex ( TSEC ) , which partners a selective strogen receptor modulator ( SERM ) with an estrogen [ 2 ] .
The first SEC to reach advanced clinical development is a combination of he SERM bazedoxifene ( BZA ) with conjugated estrogens ( CE ) .
The first SEC to reach advanced clinical development is a combination of he SERM bazedoxifene ( BZA ) with conjugated estrogens ( CE ) .
The first SEC to reach advanced clinical development is a combination of he SERM bazedoxifene ( BZA ) with conjugated estrogens ( CE ) .
The first SEC to reach advanced clinical development is a combination of he SERM bazedoxifene ( BZA ) with conjugated estrogens ( CE ) .
All Topics